Scarica l'app Stockscreener
14.54
6.02%
-0.9001
Precedente Chiudi:
$15.44
Aprire:
$15.44
Volume 24 ore:
1.89M
Relative Volume:
0.30
Capitalizzazione di mercato:
$2.03B
Reddito:
$67.67M
Utile/perdita netta:
$-412.69M
Rapporto P/E:
-3.7997
EPS:
-3.8266
Flusso di cassa netto:
$-395.87M
1 W Prestazione:
-17.37%
1M Prestazione:
+18.93%
6M Prestazione:
+39.79%
1 anno Prestazione:
+19.33%
Intervallo 1D:
$14.49
$15.44
Intervallo di 1 settimana:
$14.51
$18.11
Portata 52W:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
14.54 | 2.16B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
487.46 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
661.16 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.24 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
307.64 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.81 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Intellia Therapeutics Inc. (NTLA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success - Yahoo Finance
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns - Yahoo Finance
NTLA Stock Price Prediction 2025-2026 | Intellia Therapeutics Inc Forecast - 24/7 Wall St.
(NTLA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics - Yahoo Finance
Price to earnings forward of Intellia Therapeutics, Inc. – LS:A2AG6H - TradingView
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo
Intellia CFO Edward Dulac III sells $84,186 in stock By Investing.com - Investing.com Nigeria
Intellia CFO Edward Dulac III sells $84,186 in stock - Investing.com
Form 4 Intellia Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Intellia Therapeutics (NTLA) VP sells shares to cover RSU tax - Stock Titan
Intellia (NTLA) CFO’s 4,677-share sale executed under 10b5-1 plan - Stock Titan
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia lures 13 new employees with 53,250 stock awards - Stock Titan
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
NTLAIntellia Therapeutics Inc Forecast, Target Price - Finviz
Investor Alert: Robbins LLP Informs Stockholders of the Intellia Therapeutics, Inc. Class Action - GuruFocus
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance
Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] Intellia Therapeutics, Inc. SEC Filing - Stock Titan
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% - The Globe and Mail
Investor Sentiment Divided in Healthcare Sector: Intellia Therap - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA): Can Innovation Justify the Buzz? - Kalkine Media
Price to book forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Price to earnings forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Price to book forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Enterprise value to revenue forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Enterprise value to revenue forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Price to sales forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView
Enterprise value to EBIT forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Price to sales forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Enterprise value to EBITDA forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView
Liquidity Mapping Around (NTLA) Price Events - Stock Traders Daily
Certain Stock Options of Intellia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2026. - marketscreener.com
Price to earnings forward of Intellia Therapeutics, Inc. – BOATS:NTLA - TradingView
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics - The National Law Review
Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Sh - The National Law Review
Intellia Therapeutics Inc (NTLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intellia Therapeutics Stock Short Interest Rises to 45.4% - Moomoo
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI
Intellia Therapeutics, Inc. Actuals & Estimates (NASDAQ:NTLA) - TradingView
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Intellia Therapeutics Inc Azioni (NTLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 02 '26 |
Sale |
18.00 |
4,677 |
84,186 |
156,286 |
3.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):